BIOMARIN PHARMABIOMARIN PHARMABIOMARIN PHARMA

BIOMARIN PHARMA

No trades
See on Supercharts

BM8 fundamentals

An in-depth look to BIOMARIN PHARMA operating, investing, and financing activities

BM8 free cash flow for Q3 24 is 172.04 M CHF. For 2023, BM8 free cash flow was 52.68 M CHF and operating cash flow was 134.09 M CHF.

Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: CHF
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM
Free cash flowYoY growth